Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by Proton3on Oct 07, 2021 11:03am
146 Views
Post# 33979816

RE:RE:RE:RE:RE:RE:RE:Establishes On-Site Clinic

RE:RE:RE:RE:RE:RE:RE:Establishes On-Site Clinic There is a ZERO percent chance he is back. When a pro analyst downgrades by 70% it means he made a big mistake and he has no confidence in them, don't get silly. SP has only tanked every week since that pro left. The NR today is a joke. People thought this would happen in Q1 but to a much larger audience that what they are offering.

You literally have to be in their special program to even get the test. Moving at a snails pace you can see why the analyst and market did not like this approach. Aristotle test number will be very low for a while I suspect. They will now need to 3-4X covid revenue and avoid offerings or dilution to have a chance to go up over next couple quarters. Would offer you all luck, but there almost no chance at least for a year or two here unless a miracle hits.


<< Previous
Bullboard Posts
Next >>